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Abstract: OBJECTIVE To evaluate whether pretreatment with metformin (MET) is associated with
less stroke severity and better outcome after IV thrombolysis (IVT), we analyzed a cohort of 1,919
patients with stroke with type 2 diabetes mellitus in a multicenter exploratory analysis. METHODS Data
from patients with diabetes and ischemic stroke treated with IVT were collected within the European
Thrombolysis in Ischemic Stroke Patients (TRISP) collaboration. We applied propensity score matching
(PSM) to obtain balanced baseline characteristics of patients treated with and without MET. RESULTS
Of 1,919 patients with stroke with type 2 diabetes who underwent IVT, 757 (39%) had received MET
before stroke (MET+), whereas 1,162 (61%) had not (MET-). MET+ patients were younger with a male
preponderance. Hypercholesterolemia and pretreatment with statins, antiplatelets, or antihypertensives
were more common in the MET+ group. After PSM, the 2 groups were well balanced with respect to
demographic and clinical aspects. Stroke severity on admission (NIH Stroke Scale 10.0 ± 6.7 vs 11.3 ±
6.5), 3-month degree of independence on modified Rankin Scale (2 [interquartile range (IQR) 1.0-4.0] vs
3 [IQR 1.0-4.0]), as well as mortality (12.5% vs 18%) were significantly lower in the MET+ group. The
frequency of symptomatic intracerebral hemorrhages did not differ between groups. HbA1c levels were
well-balanced between the groups. CONCLUSIONS Patients with stroke and diabetes on treatment with
MET receiving IVT had less severe strokes on admission and a better functional outcome at 3 months.
This suggests a protective effect of MET resulting in less severe strokes as well as beneficial thrombolysis
outcome.
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To evaluate whether pretreatment with metformin (MET) is associated with less stroke severity and
better outcome after IV thrombolysis (IVT), we analyzed a cohort of 1,919 patients with stroke with type
2 diabetes mellitus in a multicenter exploratory analysis.
Methods
Data from patients with diabetes and ischemic stroke treated with IVT were collected within the
European Thrombolysis in Ischemic Stroke Patients (TRISP) collaboration. We applied propensity score
matching (PSM) to obtain balanced baseline characteristics of patients treated with and without MET.
Results
Of 1,919 patients with stroke with type 2 diabetes who underwent IVT, 757 (39%) had received MET
before stroke (MET+), whereas 1,162 (61%) had not (MET−). MET+ patients were younger with a male
preponderance. Hypercholesterolemia and pretreatment with statins, antiplatelets, or antihypertensives
were more common in the MET+ group. After PSM, the 2 groups were well balanced with respect to
demographic and clinical aspects. Stroke severity on admission (NIH Stroke Scale 10.0 ± 6.7 vs 11.3 ±
6.5), 3-month degree of independence on modified Rankin Scale (2 [interquartile range (IQR) 1.0–4.0]
vs 3 [IQR 1.0–4.0]), as well as mortality (12.5% vs 18%) were significantly lower in theMET+ group. The
frequency of symptomatic intracerebral hemorrhages did not differ between groups. HbA1c levels were
well-balanced between the groups.
Conclusions
Patients with stroke and diabetes on treatment with MET receiving IVT had less severe strokes on
admission and a better functional outcome at 3 months. This suggests a protective effect of MET resulting
in less severe strokes as well as beneficial thrombolysis outcome.
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Diabetes mellitus is a known risk factor for stroke and asso-
ciated with a higher rate of complications after thrombolysis
as well as less favorable clinical outcome.1 Around 15% of
patients with ischemic stroke eligible for thrombolysis have
type 2 diabetes mellitus.2Due to demographic changes as well
as unfavorable lifestyle factors in industrialized countries, the
incidence of type 2 diabetes mellitus is rising.3
For treatment of type 2 diabetes, metformin (MET) is available
as an oral antidiabetic prodrug of the biguanide class and widely
used as first-line treatment in addition to lifestyle mod-
ifications.4 MET reduces hepatic glucose production and in-
testinal glucose resorption and increases glucose uptake into
muscle tissue. In addition to its antidiabetic properties, MET
has been suggested to exert beneficial effects in cardiovascular
disease bymaintaining glycemic control without hypoglycemia,
improving lipoprotein metabolism, and protecting endothelial/
vascular function.5,6 Experimental stroke data suggest neuro-
protective effects of chronic MET treatment, possibly through
modification of 59 adenosine monophosphate-activated pro-
tein kinase (AMPK) activity, an enzyme involved in cellular
energy regulation.7
Motivated by the experimental evidence suggesting cardio-
vascular protection afforded by MET and the fact that a rele-
vant number of patients with stroke have diabetes, the aim of
this multicenter study was to evaluate whether pretreatment
with MET affects initial stroke severity and results in better
outcomes of thrombolysis in patients with acute ischemic
stroke with type 2 diabetes mellitus.
Methods
Study design and study population
For this multicenter retrospective analysis, as a joint initia-
tive of 15 stroke centers within the European Thrombolysis
in Ischemic Stroke Patients (TRISP) collaboration, data
were collected from patients with acute ischemic stroke
treated with IV thrombolysis (IVT) without endovascular
treatment.8 The participating institutions were stroke cen-
ters according to national criteria or criteria of the European
Stroke Organisation.9
Standard protocol approvals, registrations,
and patient consents
The ethics committee in Zurich, Switzerland (KEK-ZH:
2014-0304) approved the study. Additional local ethical ap-
proval differed across centers and was obtained if required.
Data collection
Data for all patients were collected using a standardized form
with predefined variables as described previously.10,11 Local
TRISP investigators completed the form systematically and
retrospectively using data from prospectively composed in-
hospital thrombolysis registries, as done previously.11 Com-
pleted forms with encrypted data from all centers were sent to
the coordinating center in Zurich for merging and analysis.
Only data from patients diagnosed with type 2 diabetes
mellitus before stroke or at the time of stroke based on ad-
mission HbA1c values ≥6.5% were included.12,13
Baseline data analysis
For baseline data analysis, the following prospectively ascer-
tained variables with predefined definitions10were used: age, sex,
hypertension, hypercholesterolemia, coronary heart disease,
atrial fibrillation, current smoking, prior stroke, prestroke med-
ication (antihypertensives, statins, antiplatelets, anticoagulants,
including the use vs nonuse of MET), clinical (stroke-to-needle
time) and laboratory findings (admission blood pressure, pla-
telets, glucose, creatinine, international normalized ratio [INR]),
and stroke etiology according to the Trial of Org 10172 in Acute
Stroke Treatment (TOAST) criteria.14 Stroke-to-needle time
was defined by the interval between first symptom onset and the
application of IVT. In case information about antidiabetic
treatment was not part of the thrombolysis registry, this in-
formation was obtained from patient charts.
Outcome measures
The objective of our study was to address the influence ofMET
on primary and secondary outcomes. These were the modified
Rankin Scale (mRS) for 3-month functional impairment and
admission NIH Stroke Scale (NIHSS) for stroke severity as
primary outcomes. Secondary outcome measures were mor-
tality (all causes) within 3 months of stroke and symptomatic
intracranial hemorrhage (sICH) according to the European
Cooperative Acute Stroke Study II criteria.15
Sample size considerations
The number of confounders in this study was 19; together
with the treatment group (MET+/MET−), 20 independent
variables resulted. Without variable selection procedures, one
can assume that 10 observations (continuous outcome) or 10
events (binary outcome) per independent variable are suffi-
cient to estimate an adjusted treatment effect of MET. For
a binary outcome, e.g., mortality within 3 months of stroke,
with an anticipated prevalence of between 10% and 15%, 10
events per variable would result in 1,334–2,000 patients to
include.
Glossary
AMPK = 59 adenosine monophosphate-activated protein kinase; CI = confidence interval; INR = international normalized
ratio; IVT = IV thrombolysis;MET = metformin;mRS = modified Rankin Scale;NIHSS = NIH Stroke Scale;OR = odds ratio;
PSM = propensity score matching; TOAST = Trial of Org 10172 in Acute Stroke Treatment; TRISP = Thrombolysis in
Ischemic Stroke Patients; sICH = symptomatic intracranial hemorrhage; SMD = standardized mean difference.
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Descriptive statistics
Descriptive statistics include mean and SD for continuous
variables, median and interquartile range for ordinal variables,
and number and percentage of total for categorical variables.
These were compared between MET treatment groups using
the independent samples Wilcoxon test for continuous vari-
ables or χ2 test for categorical variables. Balancing of baseline
characteristics before and after matching was assessed with
the absolute standardized mean difference for continuous
variables and the absolute mean difference for categorical
variables, both abbreviated SMD.
Propensity score matching and
multiple imputation
We used a propensity score matching (PSM) approach to
balance baseline characteristics between the treatment
groups. The propensity score was the probability of receiving
metformin (MET+), and was estimated from a logistic re-
gression model including variables potentially influencing the
treatment group and the defined outcome measures. Patients
with missing outcome variables or unspecified MET status
were excluded from the analysis. Variables in the PSM were
selected based on previous studies and judgment of the
investigators (L.P.W., S.W.), namely age, sex, hypertension,
hypercholesterolemia, coronary heart disease, atrial fibrilla-
tion, current smoking, prior stroke, prior treatment with
antihypertensives, statins, antiplatelets, anticoagulants, blood
pressure on admission (systolic and diastolic), glucose, cre-
atinine, platelets, INR on admission, and stroke etiology.
Missing values were age (0%), sex (0%), hypertension (0%),
hypercholesterolemia (0.5%), coronary heart disease (0.2%),
atrial fibrillation (0.7%), current smoking (20.8%), prior
stroke (0.4%), prior treatment with antihypertensives
(27.3%), statins (5.6%), antiplatelets (1%) or anticoagulants
(0.9%), blood pressure on admission (systolic 7% and di-
astolic 7.1%), glucose (3.7%), creatinine (3.4%), platelets
(17.8%), INR on admission (29.7%), as well as stroke etiology
according to the TOAST criteria (1.7%).
For covariates with missing values, multiple imputation using
chained equations assuming missingness at random in com-
bination with PSM was carried out, following a recently
published approach by Mitra and Reiter.16 In brief, 100-fold
multiple imputation was applied to the data set with missing
values (m = 100). For each of these 100 datasets, a propensity
score for being in the MET+ group was estimated. Then, the
100 estimated propensity scores for each patient were aver-
aged for substantial bias reduction, resulting in a single pro-
pensity score for each patient. The described procedure was
repeated 100 times, in order to increase precision (r = 100).
PSM was performed using an “optimal” algorithm aiming to
find the samples with the smallest average absolute distance
across all the matched pairs. Program code will be made
available upon request by the authors. Balancing of baseline
characteristics after matching was again assessed with the
SMD. Covariates with an SMD <0.1 were considered
balanced.17
Comparison of outcomes
To report on the raw comparison of outcomes between
treatment groups, we used the Wilcoxon test for continuous
and ordinal outcomes and χ2 tests for categorical outcomes.
Outcomes of the matched samples were compared with either
McNemar tests (for categorical outcomes) or paired Wilcoxon
tests (for continuous/ordinal outcomes). Specifically, a variant
of theWilcoxon test able to address ties was used.18The paired
versions were used to account for dependencies due to
matching. The results from multiply imputed datasets were
combined using the Rubin rule as well as a recently proposed
formula for combining p values based on z transformation.19
Including the study center as matching variable was not fea-
sible because it led to loss of cases in the matching process.
Therefore, we addressed the potential confounding effect of
study center by fitting 2-level random intercept models with
study center, as well as matched case–control pairs as random
intercepts, and treatment group “MET” as fixed effect. NIHSS
on admission was not used for matching, as it was considered
an outcome variable. Onset-to-treatment time was also not
included in the model as it represents a hospital-dependent
variable and both groups showed a balanced distribution.
Linear mixed effects regression models were used for the
continuous or ordinal outcome variables, as well as logistic
regression for the binary outcomes. The resulting treatment
effect of metformin was shown as β coefficients, or odds ratios
(OR), including 95% confidence intervals (CIs). In the sub-
group of patients in theMET+ group, the association between
MET dose (in 1,000 mg) and outcomes was addressed with
linear and logistic regression, including again random inter-
cepts for study center.
All data analyses were conducted using R, version 3.6.0 for
Windows (R-project.org/) and the packages tableone, mice,
MatchIt, VIM, cobalt, ggplot2, lmer, and glmer.
The study was reported according to the STROBE (Strength-
ening the Reporting of Observational Studies in Epidemiology)
guidelines for observational studies.20
Data availability
Anonymized data will be shared by request from any qualified
investigator.
Results
Study population and baseline characteristics
Among 10,513 TRISP patients, 2,048 (19.5%) were individ-
uals with diabetes. Of these, 31 (1.5%) were either diagnosed
with type 1 diabetes or diabetes type was not specified (n = 25,
1.2%), so that they were excluded from further analyses.
Seventy-three patients (3.5%) had missing values in at least
one outcome variable or an unspecified MET status, and were
also excluded from the analysis (figure 1).
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Of the remaining 1,919 patients, 757 (39%) had been treated
with metformin before stroke (MET+), whereas 1,162 (61%)
had not received prestroke metformin treatment (MET−).
Mean age was 71 years in the MET+ and 74 years in the
MET− group (SMD 0.240). There were substantial differ-
ences in the distribution of creatinine on admission between
groups before matching with lower levels in the MET+ group.
MET+ patients had a male preponderance. Hypercholester-
olemia and pretreatment with statins and antihypertensives
were more common in the MET+ group, whereas atrial fi-
brillation and pretreatment with anticoagulants were more
common in the MET− group. Table 1 shows descriptive
statistics for the baseline covariates before and after matching,
but without multiple imputation. The comparison of baseline
characteristics after imputation is shown for a single randomly
chosen imputed dataset in table 2. Figure 2 demonstrates
SMD before and after matching for each confounder variable.
Matching achieved balancing across all baseline variables
(SMD <0.1).
Outcome analysis
Raw results for the outcomes of the unmatched data are
reported in table 3. NIHSS on admission, mRS after 3
months, and mortality were lower in the MET+ group com-
pared to MET−. The occurrence of sICH did not differ
significantly.
Analysis of the outcomes for the multiply imputed and pro-
pensity score matched pairs is shown in table 3. Mortality in
the MET+ group was 12.5% (95% CI, 10.3%–15.2%), and
18.0% (95% CI, 15.3%–20.9%) in the MET− group (p =
0.008). The occurrence of sICH did not differ significantly
between treatment groups, but mean NIHSS on admission
was lower in the MET+ patients (10.0 vs 11.3; p < 0.001), as
was median mRS after 3 months (2.0 in MET+, and 3.0 in
MET−; p < 0.001). Figure 3 shows the distribution of mRS
categories for the unmatched and matched cohorts in the 2
patient groups. When adjusting for study center, the results of
the random intercept models after matching revealed a lower
NIHSS on admission (−1.05; 95% CI, −1.72 to −0.38),
a lower mRS at 3 months (−0.39; 95% CI, −0.59 to −0.20), as
well as a lower chance of dying within 3 months (OR, 0.63;
95% CI, 0.47–0.84) in MET+ patients. No differences were
found for sICH. All results can be found in supplementary
table 1 at doi.org/10.5061/dryad.s087hm4.
Analysis of MET doses in correlation to
outcome and distribution of HbA1c levels
In order to assess a potential dose-dependency of MET
pretreatment with outcome, we analyzed the daily dose of
MET (in 1,000 mg) before stroke, which was available in
687 (90.8%) out of 757 MET+ patients, in correlation to
our outcome parameters NIHSS on admission, mRS after 3
months, mortality, and sICH. We found no significant as-
sociation of MET dose (figure 4A). In addition, we assessed
HbA1c levels as a measure of diabetes control between
MET+ and MET− groups. Information on HbA1c levels
was available in 1,223 (63.7%) out of 1,919 patients. HbA1c
levels were balanced after matching (SMD = 0.091,
figure 4B).
Figure 1 Flowchart of patients included in this study
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Discussion
This multicenter observational study revealed the following
key findings: patients with diabetes pretreated withMET who
had an acute ischemic stroke and received thrombolysis had
less severe strokes on admission and better functional out-
come at 3 months compared to those not pretreated with
MET. In addition, patients pretreated with MET showed
a lower mortality rate after receiving IVT. The effect remained
stable after PSM for a large number of potential confounders.
Table 1 Patient characteristics
At baseline After matching
MET+ (n = 757) MET2 (n = 1,162) p Valuea SMD MET2 (n = 757) SMD
Demographic data
Age, y (SD) 71.4 (9.5) 73.8 (10.6) <0.001 0.240 71.8 (10.9) 0.043
Female, n (%) 279 (36.9) 495 (42.6) 0.014 0.057 299 (39.5) 0.026
Risk factors, n (%)
Hypertension 673 (88.9) 1,008 (86.7) 0.184 0.022 656 (86.7) 0.022
Hypercholesterolemia 480 (63.6) 619 (53.6) <0.001 0.100 448 (59.3) 0.042
CHD 182 (24.1) 306 (26.4) 0.288 0.023 182 (24.1) <0.001
Atrial fibrillation 175 (23.3) 420 (36.4) <0.001 0.131 186 (24.8) 0.015
Current smoking 94 (18.3) 170 (16.9) 0.568 0.013 117 (18.2) 0.001
Prior stroke 145 (19.3) 271 (23.4) 0.040 0.041 146 (19.3) 0.001
Prestroke medication, n (%)
Antihypertensives 497 (79.6) 541 (70.1) <0.001 0.096 404 (76.2) 0.034
Statins 342 (48.6) 368 (33.2) <0.001 0.155 311 (43.4) 0.052
Antiplatelets 421 (56.1) 556 (48.3) 0.001 0.078 404 (53.9) 0.022
Preanticoagulants 42 (5.6) 80 (7.0) 0.272 0.014 47 (6.3) 0.007
Clinical measures, mean (SD)
Systolic blood pressure, mmHg 159.3 (25.0) 158.7 (25.3) 0.619 0.024 158.7 (25.9) 0.023
Diastolic blood pressure, mmHg 84.1 (16.7) 84.4 (16.7) 0.598 0.022 83.3 (16.2) 0.047
Glucose on admission, mmol/L 9.4 (3.5) 9.6 (4.0) 0.609 0.057 9.4 (3.9) 0.002
Creatinine on admission, μmol/L 87.1 (47.7) 102.0 (63.0) <0.001 0.267 90.6 (46.6) 0.075
Platelets on admission, 109/L 232.4 (67.9) 243.1 (87.0) 0.125 0.136 234.1 (74.1) 0.024
INR on admission 1.0 (0.2) 1.1 (0.1) <0.001 0.165 1.0 (0.1) 0.089
Stroke-to-needle time, min 161.8 (98.5) 158.0 (105.8) 0.525 0.037 158.4 (120.5) 0.030
Stroke etiologyb (%) <0.001 0.071 0.027
Cardioembolic 248 (33.4) 503 (43.9) 272 (36.4)
Large artery atherosclerosis 227 (30.6) 269 (23.5) 209 (27.9)
Small artery occlusion 78 (10.5) 74 (6.5) 61 (8.2)
Other 13 (1.8) 24 (2.1) 18 (2.4)
Undetermined 58 (7.8) 117 (10.2) 74 (9.9)
>1 Etiology 118 (15.9) 158 (13.8) 114 (15.2)
Abbreviations: CHD = coronary heart disease; INR = international normalized ratio; MET = metformin; SMD = absolute standardized mean difference.
Clinical characteristics of patient groups with (MET+) or without (MET−) metformin treatment.
a Wilcoxon test for continuous variables reported asmean (SD) and χ2 test for categorical variables reported as frequencies (percentage of the available data).
b Stroke etiology was classified according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria.11
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One possible mechanism of MET-induced protection in
stroke is chronic activation of AMPK, a major sensor of en-
ergy balance, in a nitrite oxide–dependent fashion.21 AMPK is
highly expressed in neurons and activated under low cellular
energy conditions, e.g., cerebral ischemia.22 Li et al.22 in-
vestigated the effects of MET in experimental stroke and
showed that acutely administered MET exacerbated stroke
damage through enhanced AMPK activation leading to met-
abolic dysfunction with increased lactate levels. In contrast,
chronic MET administration diminished stroke-induced lac-
tate formation and reduced stroke-enhanced cerebral AMPK
activation. Possibly, long-term activation of AMPK due to
Table 2 Characteristics of patients at baseline after matching (imputed data set)a
MET+ (n = 757) MET2 (n = 757) SMD
Demographic data
Age, y (SD) 71.4 (9.5) 71.8 (10.9) 0.043
Female 279 (36.9) 299 (39.5) 0.026
Risk factors, n (%)
Hypertension 673 (88.9) 656 (86.7) 0.022
Hypercholesterolemia 481 (63.5) 450 (59.4) 0.041
CHD 183 (24.2) 182 (24.0) 0.001
Atrial fibrillation 176 (23.2) 187 (24.7) 0.015
Current smoking 135 (17.8) 139 (18.4) 0.005
Prior stroke 145 (19.2) 147 (19.4) 0.003
Prestroke medication, n (%)
Antihypertensives 613 (81.0) 578 (76.4) 0.046
Statins 359 (47.4) 325 (42.9) 0.045
Antiplatelets 424 (56.0) 410 (54.2) 0.018
Preanticoagulants 42 (5.5) 49 (6.5) 0.009
Clinical measures, mean (SD)
Systolic blood pressure, mmHg 159.6 (24.8) 158.8 (25.9) 0.032
Diastolic blood pressure, mmHg 84.1 (16.8) 83.2 (16.2) 0.055
Glucose on admission, mmol/L 9.4 (3.5) 9.4 (3.9) 0.007
Creatinine on admission, μmol/L 87.0 (47.7) 92.0 (51.7) 0.101
Platelets on admission, 109/L 232.5 (71.3) 238.3 (79.8) 0.077
INR on admission 1.0 (0.2) 1.0 (0.1) 0.028
Stroke-to-needle time, min 161.4 (96.8) 158.4 (120.2) 0.028
Stroke etiologyb (%) 0.021
Cardioembolic 254 (33.6) 274 (36.2)
Large artery atherosclerosis 229 (30.3) 213 (28.1)
Small artery occlusion 78 (10.3) 61 (8.1)
Other 13 (1.7) 18 (2.4)
Undetermined 62 (8.2) 74 (9.8)
>1 Etiology 121 (16.0) 177 (15.5)
Abbreviations: CHD = coronary heart disease; INR = international normalized ratio; MET = metformin; SMD = standardized mean difference.
Values are n (%) or mean (SD). Clinical characteristics of patient groups with (MET+) or without (MET−) metformin treatment.
a Propensity score matching with demonstration of one of the imputed data sets randomly chosen: r = 12 (augmented), m = 73 (within).
b Stroke etiology was classified according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria.11
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chronic MET treatment might increase lactate levels in the
intact brain as a sublethal (preconditioning) metabolic stress
resulting in a tolerant state, thereby rendering the brain less
vulnerable to subsequent injury. In case of stroke, patients pre-
treated with MET might therefore be more tolerant to ische-
mia, with fewer symptoms and better recovery. Strikingly,MET
may exert its role in cardioprotection via similar mechanisms.
Increased phosphorylation of AMPK and endothelial nitric
oxide synthase and increase in PGC-1a expression in car-
diomyocytes with a positive effect on mitochondrial structure
leading to increased myocardial resistance to ischemia–
reperfusion injury have been demonstrated.23,24
Our results showing no statistically relevant difference between
admission glucose levels of MET+ compared to MET− patients
(p = 0.609, table 1) support the hypothesis of MET-related
beneficial effects beyond glycemic control. This was further
supported by well-balanced HbA1c levels between the MET+
and MET− groups (figure 4B). As a limitation, despite the large
patient numbers, the character of a subgroup analysis with only
63.7% available data for HbA1c levels has to be taken into ac-
count. In our cohort, we could not detect a dose-dependent
effect of MET on any of the outcome measures (figure 4A),
which suggests that the clinically relevant doses used for diabetes
treatment are sufficient to exert the observed beneficial effect.
A recent Japanese study evaluated the effect of MET pre-
treatment on stroke severity and outcome in an Asian pop-
ulation of patients with stroke and diabetes and
demonstrated that MET pretreatment was associated with
milder neurologic signs and symptoms, but without signifi-
cant benefit on functional outcome.25 The patient cohort
examined by Mima et al.25 comprised a smaller collective
with 355 patients, excluded prestroke impairment of activi-
ties of daily living (mRS prior to onset ≥2), and included less
severe strokes (NIHSS on admission median of all patients
Figure 2 Balancing of baseline confounders, measured with standardized mean difference (SMD) before and after
matching
The variables were arranged in the order of de-
creasing SMD values before matching. CHD =
coronary heart disease; INR = international nor-
malized ratio.
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2, MET users 1, nonusers 2). Our study refined and extended
this finding of a beneficial effect on stroke severity as we
observed a significantly lower stroke severity among MET+
than among MET− patients with stroke, to be treated with
IVT in our much larger (n = 1919) thrombolysis cohort of
many European Centers.
More importantly and as a novelty, we observed that func-
tional outcome at 3 months was more favorable in MET+
than in MET− patients. Our results do not prove that treat-
ment with IVT is more efficient or safe in patients pretreated
with MET, as these patients showed less severe strokes on
admission demonstrated by a lower NIHSS on admission
Table 3 Comparison of outcome depending on MET treatment before and after matching
Before matching MET+ (n = 757) MET2 (n = 1,162) p Value
Clinical scores
NIHSS on admission, mean (SD) 10.0 (6.7) 11.7 (6.5) <0.001
mRS after 3 months, median [IQR] 2 (1.0–4.0) 3 (1.0–5.0) <0.001
Complications, n (%)
Symptomatic ICH (ECASS-II criteria) 39 (5.2) 58 (5.0) 0.96
Mortality within 3 months, n (%) 95 (12.5) 258 (22.2) <0.001
After matching MET+ (n = 757) MET2 (n = 757) p Value
Clinical scores
NIHSS on admission, mean (SD) 10.0 (6.7) 11.3 (6.5) <0.001
mRS after 3 months, median [IQR] 2 (1.0–4.0) 3 (1.0–4.0) <0.001
Complications, n (%)
Symptomatic ICH (ECASS-II criteria) 39 (5.2) 39 (5.2) 0.73
Mortality within 3 months, n (%) 95 (12.5) 136 (18) 0.008
Abbreviations: ECASS-II = European Cooperative Acute Stroke Study II; ICH = intracranial hemorrhage; MET =metformin; mRS =modified Rankin Scale; NIHSS
= NIH Stroke Scale.
Figure 3 Bar plots of modified Rankin Scale (mRS) categories at 3 months
MET+ indicates the group of patientswithmetformin;MET− indicates the group of patientswithoutmetformin. Top panel: unmatched patients; bottompanel:
matched pairs.
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compared to the non-pretreated (MET−) patient group. This
suggests that MET exerts protection even before stroke onset
and IVT. We therefore refrained from adjustment of groups
for NIHSS on admission. Consequently, we can assume that
at least part of the effect of MET on clinical outcome at 3
months is caused by the lower stroke severity on admission.
One limitation of the current multicenter registry study is its
observational design with a certain risk of bias from hetero-
geneity of the different contributing centers about the use vs
nonuse of MET. However, there is a standardized study ap-
proach concerning clinical and outcome measures, data col-
lection, and analysis of all centers within the TRISP network,
which has proven reliable and effective in previous
studies.26,27When adjusting for center-specific heterogeneity,
the beneficial effect of MET was preserved. We cannot rule
out that potentially unknown or unmeasured confounders
such as duration of prestroke MET as well as poststroke or
other antidiabetic medication may have introduced a bias and
added to the favorable outcome in the MET+ group. For the
clinical outcome scores, however, there is very strong evi-
dence for between-group differences, and a potentially un-
measured confounder would need to be very strong to
account for the favorable MET+ outcome, which is very un-
likely considering correction for 19 well-known covariates. In
future studies with prospective design, measures such as dis-
ease duration, time and dose of MET treatment, continuation
after stroke, and poststroke medication should be taken into
consideration to better characterize optimal treatment con-
ditions for neuroprotection in stroke.
The present study emphasizes prophylactic protective
effects of chronic MET intake in patients with stroke and
diabetes resulting in less severe stroke, better functional
outcome, and a lower mortality rate after IVT. Our data
suggest that MET should be continued as a first line treat-
ment for patients with diabetes, especially for patients with
a high risk of stroke.
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